Full Text
The Full Text of this article is available as a PDF (269.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bruzzi P. Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue. BMJ. 1998 Apr 18;316(7139):1181–1182. doi: 10.1136/bmj.316.7139.1181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bush T. L., Helzlsouer K. J. Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial. Epidemiol Rev. 1993;15(1):233–243. doi: 10.1093/oxfordjournals.epirev.a036110. [DOI] [PubMed] [Google Scholar]
- Jordan V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem Suppl. 1995;22:51–57. doi: 10.1002/jcb.240590808. [DOI] [PubMed] [Google Scholar]
- Jordan V. C. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol. 1995;35:195–211. doi: 10.1146/annurev.pa.35.040195.001211. [DOI] [PubMed] [Google Scholar]
- Karp S. E., Tonin P. N., Bégin L. R., Martinez J. J., Zhang J. C., Pollak M. N., Foulkes W. D. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997 Aug 1;80(3):435–441. doi: 10.1002/(sici)1097-0142(19970801)80:3<435::aid-cncr11>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
- Kelsey J. L., Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 1996;17:47–67. doi: 10.1146/annurev.pu.17.050196.000403. [DOI] [PubMed] [Google Scholar]
- Lenert L. A., Markowitz D. R., Blaschke T. F. Primum non nocere? Valuing of the risk of drug toxicity in therapeutic decision making. Clin Pharmacol Ther. 1993 Mar;53(3):285–291. doi: 10.1038/clpt.1993.23. [DOI] [PubMed] [Google Scholar]
- Love R. R. Antiestrogens as chemopreventive agents in breast cancer: promise and issues in evaluation. Prev Med. 1989 Sep;18(5):661–671. doi: 10.1016/0091-7435(89)90037-6. [DOI] [PubMed] [Google Scholar]
- Nease R. F., Jr, Ross J. M. The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs. Am J Med. 1995 Aug;99(2):180–189. doi: 10.1016/s0002-9343(99)80138-7. [DOI] [PubMed] [Google Scholar]
- Smigel K. Breast cancer prevention trial under scrutiny (again) J Natl Cancer Inst. 1992 Nov 18;84(22):1692–1694. doi: 10.1093/jnci/84.22.1692. [DOI] [PubMed] [Google Scholar]
- Stone R. NIH fends off critics of tamoxifen study. Science. 1992 Oct 30;258(5083):734–734. doi: 10.1126/science.1439776. [DOI] [PubMed] [Google Scholar]